Baseline history of patients using selexipag for pulmonary arterial hypertension

Since its introduction to the market in 2016, selexipag has been an alternative oral therapy among both treatment-na？ve patients and those with mono or dual therapy failure; however, limited information is available regarding the presentation and management of patients with pulmonary arterial hypertension (PAH) prior to selexipag initiation. This study examined treatment patterns, healthcare utilization, and costs in the 12 months prior to and the 6 months following selexipag initiation